All In Nutritionals
Facebook Instagram Linkedin Twitter Website
Home Blog Page 138

John Craig joins LeBeau Excel Ltd.

By
Editor
-
0
John Craig joins LeBeau Excel Ltd.

For immediate release: John Craig is joining LeBeau Excel Sales & Marketing the as new Director of Sales for English Canada on Nov 5 th 2018.
Hailing from Burlington Ontario, John and his wife, Gail, have 2 kids who are at the post-secondary and adult phases of life.

John has spent the last 9 years with VEGA holding several key sales leadership positions and helped guide the team through many changes including their meteoric rise through to the corporate sale and eventual settling in as a division of Danone. John has also managed many key accounts over his various tenures including Costco, GNC and others. John holds a BA from Western University and spent 5 years with Iovate Health Sciences as the Director of Sales previous to joining VEGA.

All of our outside salespeople, excluding Quebec, will align under this newly created role as John works closely with Deb Ritcey & Eamonn McKay to drive improvements through our team. John will also manage Shoppers Drug Mart and collaborate on LCL generally.

John brings a wealth of organizational experience and managing sales team as we push forward with our mandate to make LeBeau Excel more efficient, transparent and easy to do business with. We look forward to his contributions and collaborations as a leader in our business.

You can reach John at john@lebeauadvance.com or 647-283-6277.

Albertsons Grocer Starts E-commerce Pilot Project

By
Editor
-
0
Albertsons Grocer Starts E-commerce Pilot Project

Albertsons Cos. has entered a technology partnership to begin building a back-end infrastructure for e-commerce.

The Boise, Idaho-based grocer recently said that it has teamed up with e-grocery automation startup Takeoff Technologies to create a pilot project to create a hyperlocal micro-fulfilment centre with an existing store. Albertsons called the partnership “a major step in our commitment to being a customer-centric player in the digital food and wellness ecosystem.

The effort comes as retailers are looking to data to help inform their buying decisions. It also comes as grocers increasingly focus on the local or upstart brands that shoppers are now wanting.

Takeoff’s artificial intelligence-enabled robots can collect items for online grocery orders in minutes, at a fraction of the speed and cost of manual-picking processes. With the move, Albertsons said it’s the first national grocer to implement an automated e-commerce fulfilment solution for customers.

“If you’re a small player with a very good product or a big consumer packaged goods company with a small unit, you will struggle to get the attention of some of our larger banners,” said Narayan Iyengar, senior vice president of digital marketing and e-commerce at Albertsons.

“Investing in e-commerce directly benefits our customers, and anything that we can do to simplify their grocery shopping experience to save valuable time is a win,” Iyengar said in a statement. “While our partnership with Takeoff Technologies will streamline e-commerce fulfilment and improve our efficiencies, we’re excited that Takeoff’s AI solution will make it even easier for customers to get their groceries how and when they want.”

How will it work?

Albertsons customers will place their grocery orders online or via a mobile, and the orders are then routed to an automated system. Takeoff’s facility then takes over the fulfilment process. The AI-enabled robots and a system of totes and conveyors deliver the items to an Albertsons’ employee, who prepares the orders for customers.

The companies noted that the system slashes the amount of time for individual customer orders to be processed. And the automated warehouse is replenished daily, just as supermarket store shelves are stocked regularly, they said.

“Our e-grocery automation is a turnkey solution that uses artificial intelligence to unlock ultimate convenience for shoppers without the need of charging fees or a price premium,” said Max Pedro, co-founder and president of Waltham, Mass.-based Takeoff in a statement.

The retailer, which has nearly 2,300 stores in 35 states, noted that Takeoff’s model leverages the existing supply chain and store footprint and is flexible in picking various types of products.

 

Aura Closes $400,000 Convertible Debenture Offering

By
Editor
-
0
Aura Closes $400

 Aura Health Inc. is very pleased to announce that it has closed a non-brokered private placement offering (the “Offering”) on October 26th, 2018 (“Closing Date”) of unsecured convertible debentures bearing interest at a rate of 10% per annum, payable quarterly in arrears (each a “Debenture”, and together the “Debentures”), for gross proceeds of CAD$400,000. The proceeds of the Offering will be used by the Company for general working capital requirements and general corporate purposes.

Each Debenture is convertible at the conversion price of $0.365 (the “Conversion Price”) into units (the “Units”) consisting of one common share in the capital of the Company (each a “Common Share”, and together the “Common Shares”) and one-half of one common share purchase warrant (the “Warrants”) exercisable at the conversion price of $0.50 per Common Share for a period of 24 months from the date of issuance.

The Debentures are exercisable until October 26, 2020, or until such time that the Common Shares of the Company trade on the Canadian Stock Exchange for a period of 20 consecutive trading days at a price of $0.60, upon which the Common Shares will automatically convert into Units at the Conversion Price.

The Debentures and any securities which may subsequently be issued in relation thereto are subject to a four month and one day hold period.

Daniel Cohen, Chief Executive Officer of the Company participated in the Offering, subscribing to a $200,000 Debenture. Such participation is considered a related party transaction within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The related party transaction is exempt from minority approval, information circular, and formal valuation requirements pursuant to the exemptions contained in Sections 5.7(a) and 5.5(a) of MI 61-101, as neither the fair market value of the gross securities issued under the Offering nor the consideration paid by Daniel Cohen exceed 25% of the Company’s market capitalization.—GLOBE NEWSWIRE

About Aura Health Inc.

Aura is building an international network of vertically-integrated cannabis assets. The company has LOIs in place to acquire the majority of two Israeli assets: HolyCanna, a cultivation and nursery license holder, and CannabiSendak, the builder of a network of high-profile dispensaries. Aura also owns a 30% interest in four medical marijuana clinics in the U.S. Sun Belt, with an option to increase its interest in three of the clinics to 51%.

Weed Advisor first to offer a legal, retail credit card platform for cannabis products in Canada

By
Editor
-
0
Weed Advisor first to offer a legal

– National, independent survey shows consumer acceptance toward online and dispensary purchases –

Weed Advisor, a cannabis platform service that supplies the latest access to products, information, business solutions and consumer insights to the cannabis industry, has launched a first-to-market legal retail credit card payment processing platform for hundreds of products and counting, available at weedadvisor.com.

While other online cannabis-focused sites offer sales through e-transfers, C.O.D. transactions and third-party channels such as PayPal, as of Canadian cannabis legalization today, Weed Advisor will offer the same type of PCI compliant transactions utilized to purchase music, furniture, computer hardware & software, food & beverage, and clothing, to name a few industries – virtually everything people have come to grow accustomed to when buying online.

“Consumers look for convenience, insurance and a sense of overall security when shopping online – regardless of the product or service they plan to purchase,” says Gregory Luciani, President and CEO of Weed Advisor. “Legalization doesn’t always equate to a comfort level of use, which is exactly the problem we are addressing, as industry-wide understanding continues to evolve. We’re providing a trusted source for online purchasing that offers significant options and substance.”

This allows Weed Advisor to offer direct consumer benefits, as well as a quick and simple sales channel for retailers that may or may not have a bricks-and-mortar presence. Once a license is legally produced and accepted by Weed Advisor, it is just a matter of hours that products are filtered – as another legal step in the process – at the Weed Advisor site and ready for sale.

“This is a new business frontier in Canada, so we were careful in our approach to building block partnerships,” says Danny Gurizzan, Chief Executive Officer at PSP Card Services. “Weed Advisor’s offerings, original approach and ongoing commitment to customer service align with our own business model, which is why we chose to work with their team right out of the gate.”

Supported through multi-million dollars of investment through private equity firms, the initial rollout of the credit card payment processing platform will immediately provide select offerings upon legalization, while products will continue to be added to the in-stock listings going forward.

An early adopter and partner of the Weed Advisor platform is Snowy River International, a world-renowned cyber security firm based out of Alberta that critically ensures safe sharing of information and cyber integrity.

“Snowy River International prides itself on our work behind safety of web-based transactions,” says Wayne Ronhaar, CEO of Snowy River International. “Adding our expertise to the Weed Advisor experience in this evolving cannabis market assures we are resilient and responsive to customer needs.”

 

Two other timely initiatives that complement the new payment processing platform include:

  • In-house Weed Advisor financing options for businesses interested in the company’s proprietary B2B and B2C suite of solutions; and
  • Soon-to-be-offered Weed Advisor credit cards, offering all the benefits and security of your typical credit card.

 

INDEPENDENT ONLINE STUDY BRINGS CONSUMER OPINIONS TO LIGHT AS LEGALIZATION APPROACHES

Along with its payment platform initiative, Weed Advisor also conducted an independent national survey through its extensive database to identify and explore trends within the Canadian consumer marketplace.

 

Three key findings reveal:

  • Despite potential for lack of brand familiarity with new, wide ranging options, 63 per cent of respondents say this won’t keep them from purchasing through dispensaries and online sites, citing the upside of safety, stability, ingredient information, and a chance to try something new.
  • Legalization will open doors to friends trying/re-connecting with cannabis, according to 60 per cent of those surveyed, based on the ideas surrounding increased access and acceptance.
  • Due to long-term stereotyping and decades of negativity around cannabis use, 85 per cent believe a certain stigma will remain even after legalization.

 

Other survey results include:

  • 25 per cent plan to purchase cannabis using all three main channels – their black market source, dispensaries and online
  • “Only through web-based sales” shows the most individual promise for sales at 27 per cent, with “only at dispensaries” at 26 per cent and “only via black market” at 23 per cent
  • 62 per cent are somewhat informed about the new street laws, but feel it’s too early to truly tell what will take place regarding enforcement of legal specifics

“Clearly, Canadians have strong opinions on legalization and their approach to the changing environment around cannabis,” says Krishnan Wignarajah, Chief Operating & Information Officer at Weed Advisor. “It’s encouraging to see definitive positions taken and especially motivating for the industry since there is strong support for dispensaries and online purchasing. It speaks to Canada’s open-minded approach to this ground-breaking position on acceptance.”-CNW

METRO INC. – Dividend Notice

By
Editor
-
0

METRO INC. declares a quarterly dividend of $0.18 per common share, payable on November 13, 2018 to shareholders of record as at October 26, 2018. This quarterly dividend represents an increase of 10.8% over the same quarter last year.

About METRO INC.
With annual sales of approximately $16 billion, METRO INC. is a leader in food and pharmaceutical distribution in Québec, Ontario and Eastern Canada, where it operates or is the franchisor of a network of more than 600 food stores under several banners, including Metro, Metro Plus, Super C and Food Basics, as well as close to 700 drugstores primarily under the Jean Coutu, Brunet, Metro Pharmacy and Drug Basics banners, providing employment to 85,000 people. For more details, visit corpo.metro.ca.-CNW

(gavinbros.com)

Why Medical Marijuana Has Healthcare Companies Scrambling to Invest in the $10 Billion Industry

By
Editor
-
0
Why Medical Marijuana Has Healthcare Companies Scrambling to Invest in the $10 Billion Industry

Frost & Sullivan will host an interactive briefing discussing the medical marijuana market revenue trends and challenges.

Frost & Sullivan, the growth partnership company, announced today that it will host a live, complimentary Growth Innovation Leadership (GIL) briefing titled, “Medical Marijuana Market Trends – Future Clinical Role of Medical Marijuana & CBD,” on Tuesday, October 30, 2018, from 1:00 to 2:00 PM Pacific Time. The webinar will offer expert insight from Nitin Naik, Global Vice President, Life Sciences, Barbara Gilmore, Senior Consultant, Life Sciences, both at Frost & Sullivan, and Dr. Joseph C. Maroon, Clinical Professor and Vice Chairman, at the University of Pittsburgh.

For more information and to register for the webinar, please visit http://frost.ly/2t3.

Medical cannabis use is driving industry revenues into the billions. Investments by pharmaceutical and Big Tobacco companies in the development of cannabis and CBD-based products and devices, along with healthcare-conscious consumers having access to these products, are spurring growth. Physicians, aware of increasingly widespread medical marijuana legalization, are interested in understanding the potential of these treatments. In the US states where cannabis is approved, the use of prescription drugs, including the use of opioids, has decreased.

“The use of medical marijuana is sparking keen interest not only with investors, but also doctors and patients. All but four states in the US have legalized either medical marijuana or CBD use. There are over 770 clinical trials underway studying the use of medical cannabis in various diseases and another more than 500 trials studying the use of CBD,” noted Gilmore. “With all of these studies underway, it is interesting to note that states that have legalized marijuana for recreational use have seen a steady decrease in the number of recorded patient prescriptions. This is a trend that will be studied going forward as physicians learn more about the medical marijuana efficacy as it related to the diseases it is successfully treating.”

The informative webinar will cover key insights:

  • Learn about a variety of medical marijuana science and clinical uses/applications (patient experiences);
  • Discover health-related applications of medical marijuana based on interactions with the endocannabinoid system; and
  • Explore the latest clinical research in cancer, neurological, psychological, metabolic and pain disorders using medical marijuana.

The event will also be recorded and available for on-demand viewing at http://frost.ly/1ti.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion. -CNW

 

Organigram Announces Definitive Agreement to Acquire 25% of alpha-cannabis® Pharma GmbH

By
Editor
-
0
Organigram Announces Definitive Agreement to Acquire 25% of alpha-cannabis® Pharma GmbH

Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), a leading licensed producer of medical marijuana, is pleased to announce that it has, through its wholly-owned subsidiary 10870277 Canada Inc. (the “Purchaser” or “OGI”), executed an investment agreement dated as of October 10, 2018 with alpha-cannabis® Pharma GmbH (“Alpha-Cannabis Germany” or “ACG”) pursuant to which the Purchaser will acquire 8,333 common shares of ACG, representing a 25% stake in the capital of ACG, for aggregate proceeds of €1,625,000. The closing is subject to certain formalities under German law largely of an administrative nature.

As part of the investment and effective upon the closing of the investment, OGI’s wholly-owned subsidiary, Organigram Inc. will enter into two supply agreements with ACG: one for the supply of cannabidiol isolate from ACG to Organigram Inc., and the other for the supply of dried cannabis flower from Organigram Inc. to ACG. In addition, ACG and Organigram Inc. will enter into an agreement pursuant to which the companies will jointly evaluate and bid on certain licenses to supply medical cannabis to the German market.

In addition, upon ACG achieving certain milestones, the Purchaser will pay ACG additional consideration of €875,000 payable in common shares of OGI to be valued in accordance with a volume-weighted average price formula described in the investment agreement. The issuance of the OGI shares is subject to compliance with TSXV corporate policies.

Alpha-Cannabis’ Managing Directors Alexander Klomsdorff and newly appointed Dr. Volker Christoffel are pleased that the agreement with Organigram has now been formally finalized. ACG has been preparing the development and production of further cannabis based products for the swiftly growing German and European Markets following their recent product launch of “Cannabidiol alpha DAC”. “We look forward to a strong and fruitful partnership with our Canadian partners as we see significant potential in jointly materializing the medicinal benefits of Cannabinoids” ACG’s Managing Directors stated.

“As we continue to build the framework of our international medical business, finding the right partners in the right markets has been a priority for our company,” stated Greg Engel, CEO at Organigram. “This relationship is a perfect example of two companies coming together towards a common goal, and we’re very excited to build our business in Germany through our partners at alpha-cannabis® Pharma GmbH”

About alpha-cannabis® Pharma GmbH

Established in 2016, Alpha-Cannabis Germany is strategically positioned to serve the German medical cannabis market which is quickly becoming one of the largest markets for medical cannabis in the world. Additionally, the German market is positioned as a potential gateway to supplying other European markets. With team of highly experienced and reputable specialists from the pharmaceutical industry with scientific and business backgrounds, ACG is focused on the development, production and marketing of Cannabis based APIs (Active Pharmaceutical Ingredients) and pharmaceuticals. ACG’s activities cover the spectrum of cannabinoids. The company enjoys a strong network of professional partners throughout Germany and its recently announced launch of a CBD kit will be available in over 20,000 pharmacies throughout Germany, Austria and Switzerland.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. In anticipation of the legal adult use recreational cannabis market in Canada, Organigram has developed a portfolio of brands including The Edison Cannabis Company, Ankr Organics, Trailblazer and Trailer Park Buds. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Health Canada.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the interpretation of the Cannabis Act and promotional activities, the availability of funds, the results of financing efforts, crop yields – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information on OGI, please visit: www.Organigram.ca . -CNW

ORGANO Expands Africa Footprint into South Africa

By
Editor
-
0
ORGANO Expands Africa Footprint into South Africa

ORGANO announced it has formally expanded its Africa footprint into South Africa. The new market opened on 6 October and is now accepting customer orders and new distributor applications.

The ORGANO African Headquarters and logistics hub are located in Johannesburg.

“Our opening in South Africa represents another achievement in expanding ORGANO throughout the African Continent and is an important component of our strategic growth plan for the EMEA region,” said ORGANO Managing Director of Global Strategy, Leonard Chin. “The ORGANO brand is one of the most well known and respected brands in the global nutrition industry. This historic new market opening brings the ORGANO product lineup to millions of Africans who enjoy great tasting and healthy nutritional foods and beverages,” added Chin.

As in most markets around the world, ORGANO offers a lineup of its beverages and specialty nutritional products in South Africa.

“This latest entry into Africa represents a long term commitment to the people of Africa through our Continental Africa Plan, our broader regional growth strategy for EMEA and our global plan to make ORGANO products more broadly available around the world,” said ORGANO Chief Operating Officer, Norm Perrett.

About ORGANO
Founded in 2008 with headquarters in Vancouver, British Columbia, and formerly known as Organo Gold, ORGANO is one of the world’s leading producers and marketers of healthy, convenient and affordable nutrition and beauty products. ORGANO specializes in proprietary nutrition products, specialty brewed beverages, personal care products and cosmetics. ORGANO provides superior quality, taste and nutrition in all of its consumable products and produces and markets advanced beauty products based on proprietary botanical formulations. The company currently operates in five continents.

Cautionary Statement
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as “expect,” “believe,” “will,” “anticipates,” “believes,” “estimates,” or “plan,” by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

For more information on ORGANO and the Joint Venture, please go to http://www.organogold.com.-CNW

Publix Announces Quarterly Dividend

By
Editor
-
0
Publix Announces Quarterly Dividend

Publix Super Markets Inc. announced its board of directors declared a quarterly dividend of 26 cents per share on its common stock.

The dividend will be payable Aug. 1, 2018, either through direct deposit or mailed as a check to stockholders of record as of the close of business July 13, 2018.

Visit corporate.publix.com/stock to elect direct deposit of dividends. For individual, joint or custodial accounts, click Publix Stockholder Online at the bottom of the page. After registering for a secure and confidential online account, log in and select Dividends > Payment Preferences to elect direct deposit.

Direct deposit elections also can be made by completing the online Direct Deposit Authorization for Publix Stock Dividends form at corporate.publix.com/stock > Stockholder Resources > Forms. Print and sign the form as indicated, and then send it with a voided check to Publix stockholder services.

Publix is privately owned and operated by its more than 190,000 employees, with 2017 sales of $34.6 billion. Currently, Publix has 1,187 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina and Virginia. The company has been named one of Fortune’s 100 Best Companies to Work For in America for 21 consecutive years. In addition, Publix’s dedication to superior quality and customer service is recognized among the top in the grocery business. For more information, visit the company’s website, corporate.publix.com. —BusinessWire

Cronos Group Inc. Partners with Technion Research & Development Foundation for Cannabis Skin Care

By
Editor
-
0
Cronos Group Inc. Partners with Technion Research & Development Foundation for Cannabis Skin Care

Cronos Group Inc., announced today that it has entered into a sponsored research agreement with the Technion Research and Development Foundation of the Technion – Israel Institute of Technology (“Technion“) to explore the use of cannabinoids and their role in regulating skin health and skin disorders. The preclinical studies will be conducted by Technion over a three-year period and will focus on three skin conditions: acne, psoriasis and skin repair.

The research will be led by Technion faculty members Dr. David “Dedi” Meiri, Head, Laboratory of Cancer Biology and Cannabinoid Research and Dr. Yaron Fuchs, Head, Laboratory of Cancer Biology and Cannabinoid Research, two of the world’s leading researchers in cannabis and skin stem cell research, respectively. Dr. Meiri heads the Laboratory of Cannabis and Cancer Research with vast experience in cannabis and endocannabinoid research. Dr. Fuchs heads the Laboratory of Stem Cell Biology and Regenerative Medicine with years of experience in the biology of the skin and its pathologies. Development and implementation of the research will be conducted at Technion’s Laboratory of Cancer Biology and Cannabis Research and the Lorry I. Lokey Interdisciplinary Center of Life Sciences and Engineering in Haifa, Israel.

“We believe that the potential applications of cannabinoids to regulate skin health and treat skin disorders are vast, and we are excited to begin exploring these applications through our partnership with Technion,” said Mike Gorenstein, CEO of Cronos Group. “Using rigorous data to develop efficacious topical and transdermal formulations will be key to creating differentiated products that provide quality treatments to our consumers and strengthen our brand portfolio.”

The endocannabinoid system and the cannabinoids that modulate its activity are believed to have an important role in regulating skin health and skin disorders. The research will utilize Dr. Meiri’s cannabis strain database of over 80 cultivars and Cronos Group’s strain specific cannabis oils to isolate and investigate the effects of individual and combinations of cannabinoids, potentially including rare cannabinoids, for treating acne, psoriasis and wounds using stem cell-derived organoid cultures developed by Dr. Fuchs’ laboratory and mouse models. Cronos Group expects to be able to adapt the individual and combinations of cannabinoids to develop products for each of these three applications and expects to receive an exclusive, worldwide license to market and manufacture such products.

“We are pleased to partner with Cronos Group on this groundbreaking cannabinoid research,” said Dr. Fuchs. “Using our state of the art technology, we hope to unlock the vast therapeutic potential of cannabinoid formulations for treating skin disorders.”

“We are thrilled to begin this joint research with Dr. Meiri and Dr. Fuchs, who are among the most respected researchers in their fields,” said David Hsu, COO of Cronos Group. “Dr. Meiri’s extensive cannabis strain database and capabilities in analytical testing provide a strong foundation for researching Dr. Fuch’s world-renowned stem cell organoids. Dr. Meiri and Dr. Fuchs’ expertise coupled with Cronos Group’s competencies in the cannabis industry make us optimistic about the future opportunities from this collaboration.”

1...137138139...388Page 138 of 388

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© 2026 IHR Magazine | Canada's Natural Health Industry Authority | Le guide de l’industrie canadienne de la santé naturelle